READ-ONLY DIGITIZATION RESULT
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.
J Clin Oncol · 2026-Jun-10 · PMID 41369677
Panel Kaplan-Meier_estimate_of_PFS_in_the_ITT_analysis_population质量警告待 EXE 对齐验证
PFS
FIG A1. Kaplan-Meier estimate of PFS in the ITT analysis population assessed by blinded independent central review. HR, hazard ratio; ITT, intention-to-treat; PBO, placebo; PERT, pertuzumab; PFS, progression-free survival; TRAS, trastuzumab; TUC, tucatinib.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T17:04:00+00:00 |